Drug
Tivozanib clinical trials
Also written AV-951, KRN951 and Fotivda.
- studies test it
- 38
- open now
- 4
- in phase 3
- 4
- first study started
- 2007
Keep track of what changes. Save the tivozanib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
38 studies that test it; most in 2013 (10)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 10 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 18
- Phase 2
- 21
- Phase 3
- 4
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 16
AVEO Pharmaceuticals, Inc. (21) · Dana-Farber Cancer Institute (3) · Northwestern University (2) · Roswell Park Cancer Institute (2) · Massachusetts General Hospital (2) · Kyowa Kirin Co., Ltd. (1) · National Cancer Institute (NCI) (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Nivolumab (2) · Sorafenib (1) · Everolimus (1) · Atezolizumab (1) · Enzalutamide (1) · Durvalumab (1) · Paclitaxel (1) · Temsirolimus (1)
Studies
Open first, then newest update. How each study uses tivozanib is read from its arms, and is right about nine times in ten.
Testing it · 38
- Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersRecruitingPhase 1/2National Cancer Institute (NCI)NCT04645160Written as Tivozanib
- Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06053658Written as Tivozanib
- Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT06661720Written as Tivozanib
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesRecruitingPhase 1/2University of FloridaNCT05000294Written as Tivozanib
- RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyWithdrawnPhase 2City of Hope Medical CenterNCT07218692Written as Tivozanib
- Tivozanib + Enzalutamide in Adv Prostate CancerTerminatedPhase 2Massachusetts General HospitalNCT01885949Written as Tivozanib
- A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)CompletedPhase 3AVEO Pharmaceuticals, Inc.NCT02627963Written as Tivozanib hydrochloride
- A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular CarcinomaTerminatedPhase 1/2AVEO Pharmaceuticals, Inc.NCT03970616Written as Tivozanib
- Tivozanib Before Surgery in Treating Patients With Localized Kidney CancerWithdrawnNot applicableRoswell Park Cancer InstituteNCT01769885Written as tivozanib
- Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCCompletedPhase 1/2AVEO Pharmaceuticals, Inc.NCT03136627Written as Tivozanib
- Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedPhase 2Northwestern UniversityNCT01853644Written as Tivozanib
- Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedPhase 1/2Roswell Park Cancer InstituteNCT01835223Written as Tivozanib (1mg)
- A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell CarcinomaCompletedPhase 2AVEO Pharmaceuticals, Inc.NCT01297244Written as Tivozanib
- Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast CancerTerminatedPhase 2AVEO Pharmaceuticals, Inc.NCT01745367Written as Tivozanib Hydrochloride
- A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCCTerminatedPhase 2AVEO Pharmaceuticals, Inc.NCT01673386Written as Tivozanib
- An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).CompletedPhase 3AVEO Pharmaceuticals, Inc.NCT01076010Written as Tivozanib
- A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell CarcinomaCompletedPhase 2AVEO Pharmaceuticals, Inc.NCT00502307Written as Tivozanib (AV-951)
- A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib ProtocolsTerminatedNot applicableAVEO Pharmaceuticals, Inc.NCT01369433Written as Tivozanib + paclitaxel
- A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell CarcinomaCompletedPhase 3AVEO Pharmaceuticals, Inc.NCT01030783Written as tivozanib (AV-951)
- A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue SarcomasCompletedPhase 2Northwestern UniversityNCT01782313Written as tivozanib
See all 38 studies that test tivozanib →
Given in every arm · 1 — tivozanib is usual care beside what is tested
Codes
What other systems call tivozanib · ClinicalTrials.gg INT005730
- MeSH (NLM) C553176tivozanibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 172030934TTIVOZANIBConfirmed FDA, NLM, Wikidata
- RxNorm 2534233Confirmed FDA, Wikidata
- Wikidata Q7810457tivozanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C85444TivozanibOne source FDA
- DrugBank DB11800One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C553176 | tivozanib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 172030934T | TIVOZANIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2534233 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7810457 | tivozanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C85444 | Tivozanib | One source FDA |
| DrugBank | DB11800 | — | One source Wikidata |
Also registered as tivozanib hydrochloride (UNII 8A9H4VK35Z · RxNorm 2534245).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.